The cost-effectiveness of varicella vaccine programs for Australia

Vaccine

Volumn 18, Issue 5-6, 1999, Pages 407-415

  Scuffham, P A ^a,b   Lowin, A V ^a   Burgess, M A ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

Author keywords

Chickenpox; Cost effectiveness; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; VARICELLA ZOSTER VACCINE;

ADOLESCENT; ARTICLE; AUSTRALIA; CHICKENPOX; CHILD; COHORT ANALYSIS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION MAKING; DISABILITY; ENCEPHALITIS; FATALITY; HOSPITALIZATION; HUMAN; INFANT; NORMAL HUMAN; PNEUMONIA; PRIORITY JOURNAL; RECALL; VACCINATION;

ADOLESCENT; ADULT; AUSTRALIA; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INFANT; INFANT, NEWBORN; VACCINATION;

EID: 0032827426     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00261-3     Document Type: Article

References (26)

1. Preblud S. Varicella: complications and costs. Pediatrics. 78:1986;728-735.
2. Finger R., Hughes J.P., Meade B.J., et al. Age-specific incidence of chickenpox. Public Health Rep. 109:1994;750-755.
3. Prevention of Varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). 1996;US Department of Health and Human Services, Atlanta, GA.
4. Chant K., Sullivan E.A., Burgess M.A., et al. Varicella-zoster virus infection in Australia. Aust. NZ J. Public Health. 22:1998;413-418.
5. Scuffham P, Lowin A. The cost-effectiveness of varicella vaccine programmes in Australia. Sydney: Centre for Health Economics Research and Evaluation, Discussion Paper No. 36, Sydney, 1998.
6. Lieu T., Cochi S.H., Black S.B., et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 271:1994;375-381.
7. Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med. 49:(6):1999;763-779.
8. Beutels P., Clara R., Tormans G., et al. Costs and benefits of routine varicella vaccination in German children. J. Infect. Dis. 174:(Suppl. 3):1996;S335-S341.
9. Children's Immunisation Australia. 1995;AGPS, Canberra.
10. Skinner S., Nolan T., Bowes G. Measles-mumps-rubella and hepatitis B vaccination uptake in adolescents: a survey in metropolitan Melbourne. Med. J. Aust. 168:1998;546-549.
11. Kelley P.W., Petruccelli B.P., Stehr-Green P., et al. The susceptibility of young adult Americans to vaccine-preventable infections: a national serosurvey of US Army recruits. JAMA. 266:1991;2724-2729.
12. Kuter B.J., Weibel R.E., Guess H.A., et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 9:1991;643-647.
13. Manual of Resource Items and their Associated Costs. 1993;AGPS, Canberra.
14. General Practice in Australia. 1996;AGPS, Canberra.
15. Ferson M., Shen W., Stark A. Direct and indirect costs of chickenpox in young children. J. Paediatr. Child Health. 34:1998;18-21.
16. Caleo S., Hall J. Measles elimination. Costing of a national measles immunisation 'catch-up' program. 1997;Centre for Health Economics Research and Evaluation, Sydney.
17. Needles, syringes and sharps disposal systems. 1997;NSW Department of Public Works and Services, Sydney.
18. Guidelines for the pharmaceutical industry on the preparation of submissions to the pharmaceutical benefits advisory committee. 1995;Australian Government Publishing Service, Canberra.
19. Olsen J. On what basis should health be discounted? JHE. 12:1993;39-53.
20. Redelmeier D., Heller D., Weinstein M. Time preference in medical economics: science of religion. Med. Decision Making. 14:1994;303.
21. Weinstein M., Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N. Engl. J. Med. 296:1977;716-721.
22. Coudeville L., Paree F., Lebrun T., Sailly J.C. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 17:1999;142-151.
23. Asano Y., Suga S., Yoshikawa T., et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 94:1994;524-526.
24. Halloran M., Watelet L., Struchiner C. Epidemiologic effects of vaccines with complex direct effects in an age-structured population. Math. Biosci. 121:1994;193-225.
25. Saddler P., Floret D., Guess H., et al. Cost of varicella in France: a study in day care centers. J. Infect. Dis. 178:(Suppl. 1):1998;S58-S63.
26. Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. Cost-effectiveness of routine varicella vaccination in New Zealand. Economics Discussion Papers No. 9813, University of Otago, 1998.